apalutamide plus adt leads to survival benefit in mcspc
Published 4 years ago • 233 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
10:32
apalutamide plus adt in older patients with mcspc, nmcrpc
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
3:28
apalutamide and the titan clinical trial
-
6:44
hrqol among patients receiving apalutamide plus adt for metastatic castration-sensitive prostate can
-
50:36
what they don't tell you about androgen deprivation therapy (adt, hormone therapy)
-
2:06:21
pcl #62 the current & future landscape - metastatic castrate resistant prostate cancer-oliver sartor
-
3:11
erleada or apalutamide adt treatment
-
2:24
real-world psa responses to apalutamide or enzalutamide in mcspc
-
5:10
mcspc: treatment after progression on ar-targeted therapy
-
0:54
apalutamide combination is well tolerated in metastatic castration-sensitive prostate cancer
-
6:52
apalutamide: understanding its mechanism of action
-
10:38
updates in treatment using adt and anti-androgens
-
45:31
advances in adt: a guide for urologists and apps
-
2:49
overall survival data in mcrpc
-
2:37
arches trial: enzalutamide plus adt for mhspc
-
0:36
how is #apalutamide standard treatment beneficial to patients with node-positive prostate cancer?
-
17:02
androgen deprivation therapy and prostate cancer
-
8:33
titan phase 3 trial with apalutamide in metastatic castration sensitive prostate cancer
-
59:08
advances in adt: a guide for urologists and apps
-
1:19
role of the addition of docetaxel to adt in mhspc
-
1:03
dr. azad on the benefit of adding enzalutamide to adt in mhspc
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc